T0	Participants 55 72	autistic disorder
T1	Participants 308 360	pediatric subjects receiving aripiprazole treatment.
T2	Participants 550 609	pediatric subjects with autistic disorder, aged 6-17 years.
T3	Participants 610 642	Subjects were stratified by PAE;
T4	Participants 913 1004	316 randomized subjects, 259 (82.0%) were antipsychotic na√Øve (AN) and 57 (18.0%) had a PAE
T5	Participants 1814 1863	that younger subjects with higher baseline weight
T6	Participants 2089 2146	in younger subjects with a higher baseline weight z-score
T7	Participants 2394 2444	of children and adolescents with autistic disorder